Literature DB >> 34842278

The importance of vascular epithelial growth factor (VEGF) and inducible nitric oxide synthase (INOS) in rhinitis medicamentosa pathogenesis: An experimental rat model study.

Alev Cumbul1, Fuat Bulut2.   

Abstract

OBJECTIVE: Our aim in this study is to reveal the expression of Vascular Endothelial Growth Factor (VEGF) and Inducible Nitric Oxide Synthase (iNOS) in the pathogenesis of rhinitis medicamentosa (RM), which occurs as a result of the overdose and long-term use of topical nasal decongestants.
METHODS: In this study, 24 Wistar albino rats were divided into two groups as experimental and control groups. In the experimental group, 50 µl of 0.05% oxymetazoline (iliadin® merck) was applied intranasally to each nostril three times a day for 2 months with the help of a micropipette. 50 µl saline was applied to the control group. At the end of the second month, the rats were examined. RM was detected in the experimental group. Then the nasal tissues of the rats were removed and fixed with 10% phosphate buffered neutral formaldehyde (pH=7.4). Nasal tissues were decalcified in Morse's solution (10% sodium citrate and 22.5% formic acid). Histopathological evaluations of the preparations were stained using Masson Trichrome (TCM) and Hematoxylin Eosin (H&E) techniques and immunohistochemical examinations of the preparations were stained with VEGF and iNOS antibodies and photographed using the Leica DM6000B microscope and the Leica Application Suite Program.
RESULTS: In the RM group, we found a significant increase in VEGF and iNOS expression in the nasal mucosa compared to the control group (p<0.001). We also observed the main histopathological changes in the nasal mucosa under a light microscope, including squamous metaplasia in the epithelium of the tunica mucosa, submucosal perivascular edema and degeneration of the submucosal glands.
CONCLUSIONS: According to these results, increased expression levels of VEGF and iNOS play an important role in rebound swelling in RM pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34842278     DOI: 10.14670/HH-18-399

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  29 in total

Review 1.  Rhinitis medicamentosa: a review of causes and treatment.

Authors:  Peter Graf
Journal:  Treat Respir Med       Date:  2005

Review 2.  Angiogenesis as a therapeutic target.

Authors:  Napoleone Ferrara; Robert S Kerbel
Journal:  Nature       Date:  2005-12-15       Impact factor: 49.962

3.  Rhinitis medicamentosa. An experimental histopathological and histochemical study.

Authors:  S S Elwany; W M Stephanos
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  1983       Impact factor: 1.538

4.  Treatment of rhinitis medicamentosa with fluticasone propionate--an experimental study.

Authors:  S Elwany; S Abdel-Salaam
Journal:  Eur Arch Otorhinolaryngol       Date:  2001-03       Impact factor: 2.503

5.  The expression of iNOS and nitrotyrosine in colitis and colon cancer in humans.

Authors:  Einat Gochman; Jamal Mahajna; Pessia Shenzer; Aviva Dahan; Alexandra Blatt; Rami Elyakim; Abraham Z Reznick
Journal:  Acta Histochem       Date:  2012-03-13       Impact factor: 2.479

Review 6.  Angiogenesis in cancer and other diseases.

Authors:  P Carmeliet; R K Jain
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

7.  Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin.

Authors:  M A Goldberg; T J Schneider
Journal:  J Biol Chem       Date:  1994-02-11       Impact factor: 5.157

8.  Determination of oxidative stress and effect of erdosteine on rhinitis medicamentosa in a rat model.

Authors:  Recep Dokuyucu; Cengiz Cevik; Gul Soylu Ozler; Tumay Ozgur; Cengiz Arli; Fatih Sefil; Zafer Yonden
Journal:  Eur J Pharmacol       Date:  2014-09-18       Impact factor: 4.432

Review 9.  Diabetic Retinopathy and Diabetic Macular Edema.

Authors:  Steven R Cohen; Thomas W Gardner
Journal:  Dev Ophthalmol       Date:  2015-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.